As part of the NICE’s single technology appraisal process, this assessment critically reviewed the manufacturer’s submission related to the evidence for the clinical and cost-effectiveness of ranibizumab for the treatment of adults presenting with choroidal neovascularisation associated with pathological myopia
The manufacturer’s submission focused on a phase III trial consisting of a 3-month double-blind phase during which the efficacy and safety of ranibizumab was compared to those of verteporfin photodynamic therapy (vPDT), and a 9-month non-comparative phase which provided data on the efficacy and safety of ranibizumab only. Compared with vPDT, ranibizumab showed a significantly greater increase in best corrected visual acuity at 3 months. There were no serious adverse events during the trial but fewer ocular and non-ocular adverse events in vPDT participants. A potentially relevant comparator, bevacizumab, was not considered in the manufacturer’s submission.
Recommendations for future research included longer term follow up and head-to-head comparisons of ranibizumab with bevacizumab.
Ranibizumab is recommended by NICE as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (for further information see the NICE Guidance TA298 - http://publications.nice.org.uk/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia-ta298).
Miriam Brazzelli: email@example.com